Bisphosphonates and Bone Diseases: Past, Present and Future

Current Pharmaceutical Design

Volumn 16, Issue 27, 2010, Pages 2948-2949

  Heymann, Dominique ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BONE CELL; BONE DISEASE; CELL TYPE; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; GROWTH INHIBITION; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE RESORPTION; DIPHOSPHONATES; DRUG DESIGN; HUMANS;

EID: 78649864047     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793563572     Document Type: Editorial

References (12)

1. Francis MD, Velent DJ. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. J Musculoskeletal Neuronal Interact 2007; 7: 2-8
2. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: Molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010; 16(27): 2950-2960.
3. Dunford JE. The molecular target of nitrogen containing bisphosphonates: the molecular pharmacology of FPP synthase. Curr Pharm Des 2010; 16(27): 2961-2969.
4. Mitrofan LM, Auriola S, Mönkkönen H, Mönkkönen J. Assessment of bishosphonate activity in vitro. Curr Pharm Des 2010; 16(27): 2970-2980.
5. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Rédini, F, Heymann D. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des 2010; 16(27): 2981-2987.
6. Syddall SP, Ottewell PD and Holen I. Combined therapies of bone disease with bisphosphonates. Curr Pharm Des 2010; 16(27): 2988-2997.
7. Woodward EJ, Coleman RE. Prevention and treatment of bone metastases. Curr Pharm Des 2010; 16(27): 2998-3006.
8. Clezardin P and Massaia M. Bisphosphonates in tumor immunotherapy. Curr Pharm Des 2010; 16(27): 3007-3014.
9. Buijs Jeroen T, Kuijpers Chantal C H, van der Pluijm G. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates. Curr Pharm Des 2010; 16(27): 3015-3027.
10. Lawson MA, Ashcroft J, Croucher PI. Bisphosphonates and the treatment of multiple myeloma. Curr Pharm Des 2010; 16(27): 3028-3036.
11. Le Goff B, Guillot P, Glémarec J, Berthelot JM, Maugars Y. A comparison between bisphosphonates and other treatments for osteoporosis. Curr Pharm Des 2010; 16(27): 3037-3044.
12. Le Goff B, Berthelot JM, Maugars Y, Romas E. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 2010; 16(27): 3045-3052.